A Phase 2 interventional study of RPL554 suspension and Placebo in COPD, sponsored by Verona Pharma plc. Completed at 49 sites in 6 countries. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-06-04.
Sponsored by Verona Pharma plc (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 2 under way, 1 of them phase 3. ensifentrine · Pulmonary Disease, Chronic Obstructive.
Among the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, this one is the 6th largest by enrollment, is one of 2 that started in 2017, is one of 8 in phase 2, and was the 4th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →1 of the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive is open now, in 1 country. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States
Ages 40–80
By country, each count listing its studies:
ensifentrine: first FDA approval 2024 (OHTUVAYRE). What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 405 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 79 across the 15 interventional studies. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 4 most frequent:
This study is registered under Verona Pharma plc, one of the names counted as Merck & Co., Inc. Under that name alone:
Verona Pharma plc is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc: 1 open now, 3 under way, 1 of them phase 3. Of 23 finished, 15 (65%) have results posted.
Among the 26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc, this one is the 8th largest by enrollment, is one of 2 that started in 2017, is one of 18 in phase 2, and was the 13th registered.
Merck & Co., Inc’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2002.
1 of the studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05270525Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAEffect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207) | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Among Merck & Co., Inc’s 26 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
The study investigates the effect of 4 weeks of twice daily treatment of four different doses of RPL554 (a phosphodiesterase [PDE]3/4 inhibitor) or placebo in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Patients will be equally allocated to one of the five treatment options.
RPL554 is a dual inhibitor of PDE3 and PDE4 which are known to have a role in modulating the inflammatory airway response in respiratory diseases, including COPD. PDE3 inhibitors act as bronchodilators whilst PDE4 inhibitors have anti-inflammatory properties and there is also evidence to suggest that combined inhibition of PDE3 and PDE4 can have additive or synergistic anti-inflammatory and bronchodilator effects. PDE4 inhibitors (administered orally) have, however been associated with unfavorable gastrointestinal side effects such as nausea, emesis, diarrhea, abdominal pain, loss of appetite and weight loss. Dual PDE3/PDE4 inhibitors (administered by inhalation) have exhibited both bronchodilator and anti-inflammatory actions, with a more favorable side effect profile. It is plausible that increased efficacy with reduced side effects may be achievable with administration of a dual PDE3/4 inhibitor by the inhaled route compared to orally administered PDE3 or PDE4 inhibitors.
The purpose of this study is to investigate the dose response of RPL554 in patients with COPD over 4 weeks. This length of time should allow for study of the bronchodilator response, measured predominantly by the peak forced expiratory volume in one second (FEV1), and the anti-inflammatory response, as measured predominantly by trough FEV1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: RPL554 suspension
Drug: RPL554 suspension
Drug: RPL554 suspension
Drug: RPL554 suspension
Drug: Placebo
A dual PDE3/PDE 4 inhibitor
Placebo solution
Mean Change From Baseline in Peak FEV1 (Over 3 Hours) at Week 4
Spirometry assessments were used to assess pulmonary function including the forced expiratory volume in 1 second (FEV1). Peak FEV1 at Week 4 was defined as the maximum post-dose value among the 30 minutes, 1, 2 and 3 hour assessments collected at Visit 6. Baseline was defined as the FEV1 pre-dose assessment (-15 minutes) collected at Visit 2. A mixed model for repeated measures (MMRM) was used to model the change from baseline FEV1 using baseline FEV1 as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect. The least squares (LS) mean change from baseline FEV1 to peak FEV1 (as measured over 3 hours) at Week 4 is presented.
Time frame: Baseline (pre-dose, Visit 2) and Week 4 (Visit 6).
Mean Change From Baseline FEV1 to Morning Trough FEV1 at Week 4
Morning trough FEV1 was defined as the last pre-dose value at Visit 6. Baseline was defined as the FEV1 pre-dose assessment (-15 minutes) collected at Visit 2. MMRM was used to model the change from baseline FEV1 using baseline FEV1 as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect. The LS mean change from baseline FEV1 to morning trough FEV1 at Week 4 is presented.
Time frame: Baseline (pre-dose, Visit 2) and Week 4 (Visit 6).
Mean Change From Baseline FEV1 to Average FEV1 (Over 12 Hours) at Day 1 and Week 4
Average FEV1 over 12 hours was defined as the area under the curve from 0 to 12 hours post-dose (AUC\[0-12\]) of the FEV1 values collected during the visit under analysis (Day 1 or Week 4), divided by the length of the time interval of interest (in hours). The AUC was calculated using the trapezoidal rule. Baseline was defined as the FEV1 pre-dose assessment (-15 minutes) collected at Visit 2. MMRM was used to model the change from baseline FEV1 using baseline FEV1 as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect. The LS mean change from baseline FEV1 to average FEV1 over 12 hours at Day 1 and at Week 4 is presented.
Time frame: Baseline (pre-dose, Visit 2), up to 12 hours post-dose at Visit 2 (Day 1) and Visit 6 (Week 4).
Mean Change From Baseline in COPD Symptoms Using the Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT-PRO) Scoring at Week 4
Patients completed an electronic diary (e-diary) once daily which used the 14-item EXACT-PRO instrument to assess COPD symptoms. The EXACT-PRO instrument contains 11 respiratory symptom questions that comprise the derivative Evaluating Respiratory Symptoms (E-RS) instrument that was used to measure the effect of treatment with RPL554 on the severity of COPD symptoms overall. The E-RS tool contains 3 subscales to assess breathlessness, cough/sputum and chest symptoms. In addition to the subscale scores, a total score for the E-RS part was obtained. The raw totals for the E-RS score and for each of the subscales were converted to a scale range of 0 to 100 (least symptomatic to most symptomatic). MMRM was used to model the change from baseline using baseline as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect. Baseline was the last non-missing assessment taken prior to investigational product start date.
Time frame: Baseline (pre-dose, Visit 2) and Week 4 (Visit 6).
Mean Change From Baseline in Breathlessness as Assessed Using the St George's Respiratory Questionnaire (SGRQ) at Week 4
Patients completed the COPD specific SGRQ (SGRQ-C) consisting of 14 items each weighted from 0 to a possible maximum of 100. Items 1-7 produced the symptoms score, 9-12 the activity score, and items 8, 10, 11, 13 and 14 the impacts score. Each component sub-score was calculated as a percentage of the summed weights of each item out of the sum of the maximum possible weight for that component (range 0-100). The total score was calculated by summing the weights to all positive responses in each component, where a positive item indicated the presence of symptoms, expressed as a percentage (range 0-100). Higher scores indicate a worse outcome. Baseline assessment was pre-dose at Visit 2. MMRM was used to model the change from baseline using baseline as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, patient as random effect. The LS mean change from baseline in the total, symptoms, activity and impact SGRQ-C scores are presented.
Time frame: Baseline (pre-dose, Visit 2) and Week 4 (Visit 6).
Number of Patients With Treatment Emergent Adverse Events (TEAEs)
The number of patients with TEAEs for each the following categories are presented: any TEAE, any drug-related TEAE, any severe TEAE, any serious TEAE, serious drug-related TEAE, any TEAE leading to drug interruption, any TEAE leading to drug discontinuation, and any TEAE leading to death. All AEs which started after the first dose of investigational product.or started prior to first dose and worsened, based on the Investigator assessment of severity, on or after first dose were considered to be treatment-emergent.
Time frame: Up to end of study (approximately 6 weeks)
405 adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) were randomized into this double-blind, multicenter study, and 403 received study medication. Patients were recruited to 47 study centers in Bulgaria, Czech Republic, Germany, Poland, Romania and the United Kingdom.
| Milestone | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | RPL554 6.0 mg | Placebo |
|---|---|---|---|---|---|
| Started | 82 | 81 | 82 | 80 | 80 |
| Received treatment | 81 | 81 | 82 | 80 | 79 |
| Completed | 71 | 78 | 76 | 75 | 75 |
| Not completed | 11 | 3 | 6 | 5 | 5 |
| Withdrew: Adverse event | 6 | 0 | 4 | 2 | 3 |
| Withdrew: Withdrawal by subject | 3 | 2 | 2 | 2 | 1 |
| Withdrew: Death | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Reason not specified | 2 | 0 | 0 | 0 | 1 |
Spirometry assessments were used to assess pulmonary function including the forced expiratory volume in 1 second (FEV1). Peak FEV1 at Week 4 was defined as the maximum post-dose value among the 30 minutes, 1, 2 and 3 hour assessments collected at Visit 6. Baseline was defined as the FEV1 pre-dose assessment (-15 minutes) collected at Visit 2. A mixed model for repeated measures (MMRM) was used to model the change from baseline FEV1 using baseline FEV1 as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect. The least squares (LS) mean change from baseline FEV1 to peak FEV1 (as measured over 3 hours) at Week 4 is presented.
| Liters | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | RPL554 6.0 mg | Placebo |
|---|---|---|---|---|---|
| Mean Change From Baseline in Peak FEV1 (Over 3 Hours) at Week 4 | 0.203 (0.152 to 0.253) | 0.209 (0.160 to 0.258) | 0.257 (0.208 to 0.306) | 0.196 (0.147 to 0.246) | 0.057 (0.007 to 0.106) |
Morning trough FEV1 was defined as the last pre-dose value at Visit 6. Baseline was defined as the FEV1 pre-dose assessment (-15 minutes) collected at Visit 2. MMRM was used to model the change from baseline FEV1 using baseline FEV1 as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect. The LS mean change from baseline FEV1 to morning trough FEV1 at Week 4 is presented.
| Liters | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | RPL554 6.0 mg | Placebo |
|---|---|---|---|---|---|
| Mean Change From Baseline FEV1 to Morning Trough FEV1 at Week 4 | 0.007 (-0.038 to 0.053) | -0.019 (-0.063 to 0.025) | 0.040 (-0.003 to 0.084) | -0.026 (-0.071 to 0.018) | -0.028 (-0.072 to 0.016) |
Average FEV1 over 12 hours was defined as the area under the curve from 0 to 12 hours post-dose (AUC\[0-12\]) of the FEV1 values collected during the visit under analysis (Day 1 or Week 4), divided by the length of the time interval of interest (in hours). The AUC was calculated using the trapezoidal rule. Baseline was defined as the FEV1 pre-dose assessment (-15 minutes) collected at Visit 2. MMRM was used to model the change from baseline FEV1 using baseline FEV1 as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect. The LS mean change from baseline FEV1 to average FEV1 over 12 hours at Day 1 and at Week 4 is presented.
| Liters | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | RPL554 6.0 mg | Placebo |
|---|---|---|---|---|---|
| Day 1 | 0.088 (0.058 to 0.117) | 0.077 (0.048 to 0.107) | 0.103 (0.074 to 0.132) | 0.095 (0.065 to 0.125) | 0.008 (-0.022 to 0.038) |
| Week 4 | 0.039 (-0.007 to 0.085) | 0.052 (0.008 to 0.096) | 0.085 (0.040 to 0.130) | 0.031 (-0.014 to 0.076) | -0.033 (-0.079 to 0.012) |
Patients completed an electronic diary (e-diary) once daily which used the 14-item EXACT-PRO instrument to assess COPD symptoms. The EXACT-PRO instrument contains 11 respiratory symptom questions that comprise the derivative Evaluating Respiratory Symptoms (E-RS) instrument that was used to measure the effect of treatment with RPL554 on the severity of COPD symptoms overall. The E-RS tool contains 3 subscales to assess breathlessness, cough/sputum and chest symptoms. In addition to the subscale scores, a total score for the E-RS part was obtained. The raw totals for the E-RS score and for each of the subscales were converted to a scale range of 0 to 100 (least symptomatic to most symptomatic). MMRM was used to model the change from baseline using baseline as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect. Baseline was the last non-missing assessment taken prior to investigational product start date.
| Units on a scale | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | RPL554 6.0 mg | Placebo |
|---|---|---|---|---|---|
| E-RS Total Score | -1.07 (-2.00 to -0.14) | -1.26 (-2.16 to -0.35) | -0.80 (-1.69 to 0.10) | -0.92 (-1.81 to -0.02) | 1.19 (0.30 to 2.08) |
| E-RS Breathlessness Score | -0.46 (-0.92 to -0.01) | -0.63 (-1.07 to -0.18) | -0.48 (-0.92 to -0.04) | -0.48 (-0.92 to -0.04) | 0.47 (0.03 to 0.90) |
| E-RS Cough/Sputum Score | -0.22 (-0.50 to 0.07) | -0.30 (-0.58 to -0.03) | -0.14 (-0.41 to 0.13) | -0.21 (-0.48 to 0.06) | 0.36 (0.09 to 0.63) |
| E-RS Chest Symptoms Score | -0.39 (-0.70 to -0.08) | -0.32 (-0.62 to -0.02) | -0.19 (-0.48 to 0.11) | -0.22 (-0.52 to 0.07) | 0.35 (0.05 to 0.64) |
Patients completed the COPD specific SGRQ (SGRQ-C) consisting of 14 items each weighted from 0 to a possible maximum of 100. Items 1-7 produced the symptoms score, 9-12 the activity score, and items 8, 10, 11, 13 and 14 the impacts score. Each component sub-score was calculated as a percentage of the summed weights of each item out of the sum of the maximum possible weight for that component (range 0-100). The total score was calculated by summing the weights to all positive responses in each component, where a positive item indicated the presence of symptoms, expressed as a percentage (range 0-100). Higher scores indicate a worse outcome. Baseline assessment was pre-dose at Visit 2. MMRM was used to model the change from baseline using baseline as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, patient as random effect. The LS mean change from baseline in the total, symptoms, activity and impact SGRQ-C scores are presented.
| Units on a scale | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | RPL554 6.0 mg | Placebo |
|---|---|---|---|---|---|
| SGRQ-C Total score | -2.56 (-5.13 to 0.02) | -3.18 (-5.72 to -0.65) | -2.63 (-5.24 to -0.01) | -3.01 (-5.51 to -0.51) | -0.33 (-2.90 to 2.23) |
| SGRQ-C Symptoms score | -4.73 (-7.99 to -1.46) | -1.89 (-5.11 to 1.33) | -2.17 (-5.50 to 1.17) | -4.33 (-7.51 to -1.16) | 1.25 (-2.02 to 4.51) |
| SGRQ-C Activity score | -2.19 (-5.30 to 0.91) | -4.28 (-7.34 to -1.23) | -2.70 (-5.85 to 0.46) | -2.75 (-5.76 to 0.27) | -2.16 (-5.25 to 0.94) |
| SGRQ-C Impact score | -1.73 (-4.91 to 1.46) | -2.93 (-6.06 to 0.20) | -2.96 (-6.20 to 0.28) | -2.80 (-5.89 to 0.29) | 0.11 (-3.07 to 3.28) |
The number of patients with TEAEs for each the following categories are presented: any TEAE, any drug-related TEAE, any severe TEAE, any serious TEAE, serious drug-related TEAE, any TEAE leading to drug interruption, any TEAE leading to drug discontinuation, and any TEAE leading to death. All AEs which started after the first dose of investigational product.or started prior to first dose and worsened, based on the Investigator assessment of severity, on or after first dose were considered to be treatment-emergent.
| Patients | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | RPL554 6.0 mg | Placebo |
|---|---|---|---|---|---|
| Any TEAE | 27 | 36 | 29 | 29 | 31 |
| Any drug-related TEAE | 8 | 11 | 12 | 8 | 10 |
| Any severe TEAE | 4 | 1 | 2 | 1 | 2 |
| Any serious TEAE | 2 | 2 | 1 | 1 | 1 |
| Any serious drug-related TEAE | 1 | 1 | 0 | 0 | 0 |
| Any TEAE leading to drug interruption | 1 | 0 | 1 | 0 | 0 |
| Any TEAE leading to drug discontinuation | 6 | 1 | 4 | 2 | 2 |
| Any TEAE leading to death | 0 | 1 | 0 | 1 | 0 |
Collected over TEAEs were collected from the first dose of investigational product up to 2 weeks after the end of the study (Visit 6) (approximately 6 weeks).. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RPL554 0.75 mg | 0/81 (0%) | 2/81 (2.5%) | 20/81 (24.7%) |
| RPL554 1.5 mg | 1/81 (1.2%) | 2/81 (2.5%) | 25/81 (30.9%) |
| RPL554 3.0 mg | 0/82 (0%) | 1/82 (1.2%) | 24/82 (29.3%) |
| RPL554 6.0 mg | 1/80 (1.3%) | 1/80 (1.3%) | 19/80 (23.8%) |
| Placebo | 0/79 (0%) | 1/79 (1.3%) | 25/79 (31.6%) |
| Event | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | RPL554 6.0 mg | Placebo |
|---|---|---|---|---|---|
| Angina pectorisCardiac disorders | 0/81 | 0/81 | 0/82 | 0/80 | 1/79 |
| DeathGeneral disorders | 0/81 | 0/81 | 0/82 | 1/80 | 0/79 |
| Mitral valve incompetenceCardiac disorders | 0/81 | 1/81 | 0/82 | 0/80 | 0/79 |
| Oesophageal varices haemorrhageGastrointestinal disorders | 1/81 | 0/81 | 0/82 | 0/80 | 0/79 |
| Hepatic cirrhosisHepatobiliary disorders | 1/81 | 0/81 | 0/82 | 0/80 | 0/79 |
| Hepatic encephalopathyNervous system disorders | 1/81 | 0/81 | 0/82 | 0/80 | 0/79 |
| Completed suicidePsychiatric disorders | 0/81 | 1/81 | 0/82 | 0/80 | 0/79 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/81 | 0/81 | 0/82 | 0/80 | 0/79 |
| Obstructive pancreatitisGastrointestinal disorders | 0/81 | 0/81 | 1/82 | 0/80 | 0/79 |
| Event | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | RPL554 6.0 mg | Placebo |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 2/81 | 4/81 | 4/82 | 5/80 | 7/79 |
| HeadacheNervous system disorders | 4/81 | 4/81 | 7/82 | 4/80 | 3/79 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 4/81 | 5/81 | 3/82 | 3/80 | 6/79 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/81 | 4/81 | 6/82 | 1/80 | 1/79 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 3/81 | 1/81 | 1/82 | 1/80 | 5/79 |
| HypertensionVascular disorders | 2/81 | 1/81 | 4/82 | 3/80 | 1/79 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 0/81 | 3/81 | 1/82 | 0/80 | 0/79 |
| NauseaGastrointestinal disorders | 3/81 | 2/81 | 2/82 | 0/80 | 2/79 |
| RhinitisInfections and infestations | 1/81 | 1/81 | 0/82 | 0/80 | 2/79 |
| Supraventricular extrasystolesCardiac disorders | 0/81 | 1/81 | 0/82 | 1/80 | 2/79 |
The baseline population consists of all randomized patients.
| Age, Continuous(Years) | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | RPL554 6.0 mg | Placebo | Total Title |
|---|---|---|---|---|---|---|
| Mean | 63.6 ± 7.05 | 63.4 ± 6.40 | 62.5 ± 6.51 | 62.9 ± 6.73 | 63.5 ± 6.44 | 63.2 ± 6.61 |
| Sex: Female, Male(Participants) | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | RPL554 6.0 mg | Placebo | Total Title |
|---|---|---|---|---|---|---|
| Female | 26 | 35 | 37 | 32 | 30 | 160 |
| Male | 56 | 46 | 45 | 48 | 50 | 245 |
| Ethnicity (NIH/OMB)(Participants) | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | RPL554 6.0 mg | Placebo | Total Title |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 82 | 81 | 82 | 80 | 80 | 405 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | RPL554 6.0 mg | Placebo | Total Title |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 82 | 81 | 82 | 80 | 80 | 405 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2017 to primary completion in Jan 2018, 7 months.
Results were first posted in Jun 2019, 1 year 4 months after primary completion.
Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 7 months is below that.
Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ensifentrine
Pulmonary Disease, Chronic Obstructive →